The receptor tyrosine kinase RET is implicated in the progression of luminal breast cancers (BC) but its role in estrogen receptor (ER) negative tumors is unknown. Here we investigated the expression of RET in breast cancer patients tumors and patient-derived xenografts (PDX) and evaluated the therapeutic potential of Vandetanib, a tyrosin kinase inhibitor with strong activity against RET, EGFR and VEGFR2, in ER negative breast cancer PDX. The RT-PCR analysis of RET expression in breast tumors of 446 patients and 57 PDX, showed elevated levels of RET in ER1 and HER21 subtypes and in a small subgroup of triple-negative breast cancers (TNBC). The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER21 BC with different expression levels of RET and EGFR. Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR. The effect was associated with inhibition of RET/EGFR phosphorylation and MAP kinase pathway and increased necrosis. In a PDX model with no expression of RET nor EGFR, Vandetanib slowed tumor growth without inducing tumor regression. In addition, treatment by Vandetanib decreased expression of murine Vegf receptors and the endothelial marker Cd31 in the four PDX models tested, suggesting inhibition of tumor vascularization. In summary, these preclinical results suggest that Vandetanib treatment could be useful for patients with ER negative breast cancers overexpressing Vandetanib's main targets.
The receptor tyrosine kinase RET is implicated in the progression of luminal breast cancers (BC) but its role in estrogen receptor (ER) negative tumors is unknown. Here we investigated the expression of RET in breast cancer patients tumors and patient-derived xenografts (PDX) and evaluated the therapeutic potential of Vandetanib, a tyrosin kinase inhibitor with strong activity against RET, EGFR and VEGFR2, in ER negative breast cancer PDX. The RT-PCR analysis of RET expression in breast tumors of 446 patients and 57 PDX, showed elevated levels of RET in ER1 and HER21 subtypes and in a small subgroup of triple-negative breast cancers (TNBC). The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER21 BC with different expression levels of RET and EGFR. Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR. The effect was associated with inhibition of RET/EGFR phosphorylation and MAP kinase pathway and increased necrosis. In a PDX model with no expression of RET nor EGFR, Vandetanib slowed tumor growth without inducing tumor regression. In addition, treatment by Vandetanib decreased expression of murine Vegf receptors and the endothelial marker Cd31 in the four PDX models tested, suggesting inhibition of tumor vascularization. In summary, these preclinical results suggest that Vandetanib treatment could be useful for patients with ER negative breast cancers overexpressing Vandetanib's main targets.
Breast cancers are heterogeneous, with a multitude of molecular alterations supporting their malignant progression. 1 The use of targeted therapies in the treatment of breast cancers is increasing; especially as conventional chemotherapy affords relatively small benefits at a cost of increased toxicity. Only few tyrosine kinase-activating mutations have been identified in breast cancers. The RET (REarranged during Transfection) proto-oncogene encodes a receptor tyrosine kinase 2 and its activated signaling pathways have a pivotal role in regulating cellular survival, differentiation, proliferation and migration. 3 RET genetic alterations including germline mutations, somatic mutations, gene rearrangements, amplifications and overexpression, have been observed in several solid tumor types including breast cancers. 3 Currently, an inhibitor specific only for RET is not available, but several multikinase inhibitors have significant activity against RET. 3 Vandetanib (ZD6474) was originally developed as a second generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), but subsequently found to have more potent inhibitory effect against VEGF and RET receptors. 4 Vandetanib is approved for the treatment of metastatic medullary thyroid cancer. 5 RET overexpression or amplifications have been observed in breast cancers. 2 In a cohort of 245 invasive breast cancers, RET overexpression was found in 33% of ER1 tumors and 10% ER-tumors. 6 In addition, it has been shown that anti-RET therapies might be used in ER1 tumors to potentiate the effect of endocrine treatments in preclinical models. 7, 8 In another study performed on 108 breast cancer patients, expression of RET was found in high percentages in HER21, triple-negative and ER positive tumors. 9 Therefore, RET seems to be a promising therapeutic target in breast cancer, irrespectively of molecular subtype. If RET has been mainly investigated in luminal breast cancer, no preclinical evidence exists that it is a relevant target in the subset of ER negative tumors overexpressing RET.
To answer this question, we evaluated the expression of RET in large series of both primary breast cancers and patientderived xenografts (PDX). We found RET to be overexpressed in 32.7% of primary breast cancers and 26.3% of PDX. Treatment by Vandetanib resulted in strong tumor growth inhibition with 50% of tumor regressions in both HER21 and triple-negative tumors with RET or EGFR overexpression. The antitumor activity was associated with inhibition of MAP kinase pathway and angiogenesis.
These results suggest that Vandetanib may be an effective treatment option for the treatment of ER negative breast cancers with high expression of RET or EGFR.
Material and Methods

Patients and samples
Samples of 446 unilateral invasive primary breast tumors excised from women managed at Institut Curie-Hôpital Ren e Huguenin (Saint-Cloud, France) from 1978 to 2008 have been analyzed. All patients who entered our institution before 2007 were informed that their tumor samples might be used for scientific purposes and had the opportunity to decline. Since 2007, patients entering our institution have given their approval also by signed informed consent. This study was approved by the local ethics committee (Breast Group of Ren e Huguenin Hospital). The samples were immediately stored in liquid nitrogen until RNA extraction. A tumor sample was considered suitable for our study if the proportion of tumor cells exceeded 70%. All patients (mean age 61.8 years, range 31-91 years) met the following criteria: primary unilateral non metastatic breast carcinoma for which complete clinical, histological and biological data were available; no radiotherapy or chemotherapy before surgery; and full follow-up at Institut Curie-Hôpital Ren e Huguenin. The clinical characteristics of patient's cohort have been reported elsewhere. 10 Table S1 . Ten specimens of adjacent normal breast tissue from breast cancer patients or normal breast tissue from women undergoing cosmetic breast surgery were used as sources of normal RNA. To investigate RET prognostic relevance, area under the curve analyses were performed to identify a cut-point by which to divide the cohort into relevant RET expression subgroups. Same analyses were performed in the four subgroups separately.
The log-rank test was used to identify relations between RET mRNA expression and MFS (metastasis-free survival).
Patient-derived xenografts
Before PDX establishment, all patients had previously given their verbal informed consent for experimental research on residual tumor tissue available after histophatologic analyses. PDXs establishments have been performed after approval of the ethics committee of the Institut Curie. According to the French rules and the ethics committee of the Institut Curie, a written consent from patients to obtain residual tumor tissues is not required. In case of patient refusal that could be orally expressed or written, residual tumor tissues are not collected. This procedure was approved by ethics committees. Fifty-seven breast cancer PDX models were used in this study. They were established from patient's surgical specimens by grafting tumor fragments into the interscapular fat pad of nude mice as previously described. [12] [13] [14] In two cohorts of primary breast cancer and patient-derived xenografts, one third of tumors showed expression of at least one of the two kinase receptors, underscoring Vandetanib's potential as an effective treatment option for estrogen receptornegative breast cancers with high expression of RET or EGFR.
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AstraZeneca and Roche, respectively. Vandetanib was administered orally at a dose of 90 mg/kg 5x/week and Trastuzumab was delivered intraperitoneally at 10 mg/kg weekly.
Tumor growth was evaluated by measurement of two perpendicular diameters of tumors with a caliper twice per week. Individual tumor volumes were calculated as V 5 a 3 b 2 /2, a being the largest diameter, b the smallest. Tumor growth inhibition (TGI) of treated tumors versus controls was calculated as the ratio of the mean tumor volume in treated group to the mean tumor volume in the control group at the same time (end of the experiment). Statistical significance of TGI was calculated by the paired Student's t test by comparing the tumors volumes in the treated and control groups.
Percent change in tumor volume was calculated for each tumor using the following formula; [(Vf-V0)/V0]*100; where V0 5 Initial volume (at the beginning of treatment) and Vf 5 Final volume (at the end of treatment).
Classification of tumor response in waterfall plots: tumor regression, stabilization and progression corresponded to a percent of volume change lower, equal or >0, respectively.
Tumor sampling was performed 24 hr after the last treatment.
No specific toxicity was reported in the experiments, neither diarrhea nor rash was observed and treated mice were not noted to have any important weight loss during all the experiment period.
RNA extraction
Total RNA was extracted from breast tumor samples (biopsies and xenografts) by using acid-phenol guanidium method as previously described. 15 RNA quality was determined by electrophoresis through agarose gels staining with ethidium bromide and visualization of the 18S and 28S RNA bands under ultraviolet light.
Real-time RT-PCR
The theoretical and practical aspects of real-time quantitative PCR have been described in detail elsewhere. 16 Results are expressed as N-fold differences in Target gene expression relative to the TBP (TATA box-binding protein) gene. The N Target values of the samples were subsequently normalized in two different ways; for breast samples, values were normalized such that the median of the N Target values for the ten normal breast tissues was equal to 1. Target gene was considered to be overexpressed when values were equal or over 10.
For breast tumor xenografts, and due to the lack of corresponding normal breast tissues, the normalization was done to obtain a basal mRNA level [smallest amount of mRNA quantifiable (Ct 5 35 with 2.5 ng cDNA)] equal to 1. Threshold of mRNA values of N Target 100 was used to determine gene overexpression. Target mRNA levels that were totally absent or very low (Ct > 35; detectable but not reliably quantifiable) were scored "0" (non expressed).
The primers for the genes expression analysis were chosen with the assistance of the Oligo 6.0 program (National Biosciences, Plymouth, MN). dbEST and nr databases were scanned to confirm the total gene specificity of the nucleotide sequences chosen and the absence of single nucleotide polymorphisms. To avoid amplification of contaminating genomic DNA, one of the two primers was placed at the junction between two exons. Agarose gel electrophoresis was used to verify the specificity of PCR amplicons. The conditions of cDNA synthesis was performed as previously described. 16 To quantify murine Vegf receptors (R1, R2 and R3) and murine Pecam mRNA levels, both target genes and TBP primer pairs were selected to be murine specific when compared to the sequences of the corresponding human genes. Primers sequences used in RT-PCR analysis are listed in Supporting Information Table S2 .
Statistical analysis
The distributions of RET mRNA levels were characterized by their median values and ranges. Relationships between RET mRNA levels and molecular, histological and clinical parameters were identified using the v 2 test (relation between two qualitative parameters). Differences were considered significant at confidence levels >95% (p < 0.05). For RT-PCR analysis in PDX models, the multiple t test was used and statistical significance was determined by the Holm-Sidak method.
IHC
Xenografted tumors were fixed in 10% neutral buffered formalin, paraffin embedded, and hematoxylin-eosin-saffron (HES) stained. Outgrowths were analyzed by immunohistochemistry (IHC) for expression of biomarkers; 4 mm TMA sections were adhered to Superfrost Plus slides (MICROM, Walldorf, Germany). Immunostaining were performed in a Discovery XT Platform (Ventana Medical System, Tucson, AZ, part of Roche Diagnostics) with antigen retrieving using either EDTA buffer, pH 8 (CC1, Ventana Medical System) or citrate buffer 10 mM, pH 6, (CC2, Ventana Medical System). Primary antibodies were mostly monoclonal rabbit antibodies and parallel slides immunostained with rabbit IgG were used as negative controls. Incubation and color development involved anti rabbit multimer secondary antibody (horseradish peroxydase complex) with DAB (3,3 0 -diaminobenzidine tetrahydrochloride) as substrate (ChromoMap Kit with Anti rabbit OmniMap, Ventana Medical System). Rabbit antibodies against RET, P-EGFR (Tyr1173), P-ERK (Tyr202/204) and P-S6 (Ser240/244) were purchased from Cell Signalling Technology (Ozyme, St Quentin Yvelines, France). P-RET (Y905) antibody was purchased from R&D Systems (Lille, France).
To determine the effects of Vandetanib on tumor vascularization, tissue sections from untreated and Vandetanibtreated xenografts (n 5 3) were immunostained with the endothelial marker CD31. The CD31 antibody (clone SP38) was purchased from Spring Bioscience (Pleasanton, CA). Immunohistochemically stained slides were photographed under medium (320) or high (340) magnification, using an ImagerZ1 Zeiss microscope and an AxioCam HRc Zeiss camera. Pictures were automatically analyzed with the help of AxioVision 4.6.3 Zeiss software measurement tool (Carl Zeiss S.A.S., Le Pecq, France). The degree of vascularization was expressed as percentage of tumor area occupied by CD31-positive structures/microscopic fields encompassing only viable tumor tissue (excluding areas of necrosis). [17] [18] [19] Computerized determination of positively staining cells was performed by blanking against sections stained with an irrelevant isotype control antibody. Percent of CD31-positive area was expressed as a ratio of DAB-positive thresholded pixels compared to the number of pixels in the whole tissue sections. 19 To visualize necrosis, formalin-fixed, paraffin waxembedded tissue sections were stained with H&E, and the relative area of necrotic tissue:total tumor area was determined visually on CD31-immunostained, using interactive textual region detection morphometric image analysis. 18 
Western blotting
Proteins were extracted from tumors using RIPA buffer (50 mM Tris HCL pH 8, 150 mM NaCl, 0.5% deoxycholic acid, 0.5% Triton), supplemented with protease and phosphatase inhibitors. Lysates were resolved on 10% agarose gels, transferred into nitrocellulose membranes (Bio-Rad, Hercules, CA) and immunoblotted with a rabbit monoclonal antibody anti-phospho-FAK (Tyr861) (Abcam, Burlingame, CA) and rabbit polyclonal antibodies anti-phospho-KIT (Tyr703) (Life Technology, Saint Aubin, France) and anti-GAPDH (Ozyme).
Proteins were detected according to the ECL Western Blotting Analysis System procedure (GE Healthcare, Buckinghamshire, UK).
Results
Expression analysis of RET in breast tumors and relationship with classical clinicopathologic prognostic factors
To investigate the expression level of RET in breast tumors, we analyzed RET mRNA levels in a large series of 446 primary breast tumors from patients with known clinicopathological status and long-term outcome (Supporting Information Table S1 ) and in 10 normal breast tissue, using quantitative RT-PCR assays. Major differences in the amount of RET mRNA were observed (N RET from 0.0 to 220,3) with a median of expression of 4.86. 146 tumors (32.7%) showed a marked overexpression level (N RET 10) including two tumors (0.5%) with a very high RET overexpression (N RET 100).
We sought links between RET mRNA level and standard clinicopathological and biological factors in breast cancer (Table 1 ). Significant positive associations were observed between high RET expression and the presence of estrogen receptor a (p 5 0.00012) and progesterone receptor (p 5 0.00045). Significant correlation with the molecular subtype was also observed, the median of RET mRNA level of the 68 RH-/ERBB2-samples was 0.71, compared to 5.87, 6.45 and 6.47 for the other subtypes. Three samples (4.4%) of the 68 RH-/ERBB2-tumors and 17 samples (40.5%) of the 42 RH-/ERBB21 showed RET overexpression (N RET 10).
To further investigate whether RET mRNA expression could be of prognostic relevance, area under the curve analyses were performed. While no significant relevance was found in the total tumors population, the HR1/ERBB-group could be divided into two subgroups corresponding to low RET expression (N RET 22.8; n 5 240; 84.2%) and high RET expression (N RET > 22.83; n 5 45; 15.8%). High RET mRNA levels were significantly associated with shorter MFS (Fig. 1a ; p 5 0.0028).
Expression analysis of RET in PDX models identifies RET overexpressing tumors in all subtypes of breast cancer
To investigate RET expression in PDX models of breast cancer, we performed RT-PCR analysis of human RET in a panel of 57 PDX models previously described, 12 including 12 ER1 tumors, 7 HER21 and 38 triple-negative tumors (Supporting Information Fig. S1 ). We observed a marked human RET overexpression (N RET > 100) in 15 xenografts (26.3%). Data analysis according to the different subgroups showed that RET was highly expressed (N RET >100) in 10 of 12 luminal tumors (83%), in two out of seven HER21 tumors (29%), and in three models out of 38 triple-negative tumors (8%). Thus RET mRNA was widely overexpressed in luminal tumors, in about one third of HER21 tumors and in a small subgroup of triple-negative PDX. These percentages of overexpression are in agreement with levels of expression in breast tumors.
To confirm these results at the protein level, we performed an IHC analysis of RET protein in 4 PDX models with different expression level of RET mRNA: HBCx-5 and HBCx-24 with high expression of RET and HBCx-4B and HBCx-14 with low/no expression of RET. Protein levels detected by RET staining correlated with mRNA expression (Fig. 1b) .
These results demonstrate that RET is overexpressed in subsets of HER2 positive and triple negative breast cancers and rationalize the importance of testing the antitumor activity of a RET inhibitor in these two breast cancer subtypes.
Treatment by vandetanib induces tumor regression in both HER21 and triple-negative xenografts with high expression of RET or EGFR
To investigate whether targeting RET could inhibit tumor growth in ER-breast tumors, Vandetanib, a potent inhibitor of RET, EGFR and VEGFR2, was tested in vivo in one HER21 PDX, HBCx-5 (established from a HER21 lymphnode metastasis), and one triple-negative PDX model, HBCx-24 (established from a primary breast cancer), both with high expression of RET (Fig. 1b) . The mRNA expression of the 3 main targets RET, EGFR and Vegfr2 in the PDX cohort is shown in Supporting Information Fig. S2 ).
Treatment by Vandetanib resulted in a strong tumor growth inhibition, with TGI of 90% and 96% in HBCx-5 and HBCx-24 respectively (Fig. 2a) . To test whether Vandetanib has anti-tumor activity in tumor with low expression of RET but high expression of EGFR, and whether expression of RET or EGFR predict Vandetanib efficacy, we tested its activity in two additional triple negative PDX models: HBCx-4B, established from a lymph-node metastasis, with low level of RET and high expression of EGFR and HBCx-14, established from a primary breast tumor, with low expression of EGFR and no expression of RET (HBCx-14) (Fig. 2b) . Results showed that tumor growth was inhibited by Vandetanib in both HBCx-4B and HBCx-14 PDX, with a TGI of 96 and 80%, respectively (Fig. 2a) . Waterfalls plots were generated for the 4 PDX models (Fig. 2c) . The analysis of tumor volume changes in individual mice revealed that Vandetanib induced tumor regression in 43, 50 and 57% of animals in 3 PDX models with RET or EGFR expression, while in the HBCx-14 tumor growth was decreased without tumor regressions nor tumor stabilization (Fig. 2c and Table 2 ).
Expression levels of EGFR and RET mRNA were homogenous between mice replicates (Supporting Information Fig.  S3 ).
The four PDX models used in this study were previously characterised for their response to chemotherapy and HER2-targeted therapies. 12 Their drug response profile is summarized in Supporting Information Table S3 . HBCx-5 tumor is resistant to Trastuzumab and the HBCx-4B tumor is resistant to all chemotherapies tested. The HBCx-14 and HBCx-24 models show resistance to at least one chemotherapy currently used for the treatment of breast cancer patients such as AC or docetaxel. In summary, these data indicate that Vandetanib treatment results in tumor regression in breast cancers with high expression of RET or EGFR and resistant to other conventional therapies, such as Trastuzumab or anthracyclines/ taxanes.
Vandetanib treatment results in inhibition of RET and EGFR phosphorylation
To analyze the effect of Vandetanib treatment on RET and EGFR activity, we evaluated their phosphorylation status in the 4 PDX models. RET phosphorylation was inhibited under the effect of Vandetanib treatment in both HBCx-5 and HBCx-24 PDX models (Fig. 3a) . Phospho-EGFR was highly expressed in the HBCx-4B model, and it was decreased by Vandetanib as shown in Figure 3b .
Inhibition of RET kinase activity was further analyzed by measuring Fak phosphorylation, as Fak has been shown to signal downstream of Ret. 9 Western blot analysis of untreated and treated tumors show decreased levels of phosphorylated Fak (Tyr861) in HBCx-5 and HBCx-24 models, indicating impaired RET kinase activity (Fig. 3c) .
To analyze the pattern of distribution of the main Vandetanib targets in ER negative breast cancers, in addition to RET we measured gene expression of EGFR and VEGFR2 by RT-PCR analysis in 45 and 107 ER negative PDX and primary breast tumors, respectively. As VEGFR2 is mainly expressed by vascular endothelial cells (Supporting Information Fig. S4 ), its expression in PDX models was determined using murine specific RT-PCR primers. 20 Similar percentages of targets overexpression were found in PDX and patients tumors. 28% of patients' tumors and 27% of PDX displayed overexpression of RET, EGFR, or VEGFR2 (Supporting Information Fig. S5 ). Only one xenograft and two breast tumors showed overexpression of two targets simultaneously. As Vandetanib targets, in addition to RET and EGFR, other tyrosine kinase receptors (RTK), 21, 22 we further investigated the expression of additional targets in the 4 PDX treated models. The mRNA expression levels of human VEGFR1, VEGFR3, KIT and SRC were analyzed by RT-PCR (date not shown). In the RET negative HBCx-14 PDX model, as in the RET positive HBCx-24 model, we found high expression of KIT, as demonstrated by RT-PCR and IHC analyses (Fig. 3d) . Vandetanib has a RTK binding affinity (K d ) of 260 nM against KIT, compared to 9 and 34 nM against EGFR and RET, respectively. 21 Although the K d is tenfold lower than against EGFR and RET, treatment by Vandetanib decreased the phosphorylation of KIT protein in the 2 PDX models showing KIT expression in IHC studies (Fig. 3e) .
Overall, these results suggest that the effect of Vandetanib is associated to inhibition of receptor phosphorylation in breast tumor overexpressing Vandetanibs' main targets RET or EGFR. About one third of patients show overexpression for at least one of Vandetanib's main targets. In the PDX model with no expression of EGFR and RET, we found high expression of KIT and a decreased KIT phosphorylation in Vandetanib treated tumors.
The effect of vandetanib on tumor growth is associated with inhibition of MAP kinase pathway and tumor vasculature
To analyze the effect of Vandetanib on the two major RTK downstream oncogenic pathways, MAP Kinase and PI3 kinase pathways, we analyzed the phosphorylation of ERK and S6 in the 4 PDX models by IHC analysis. The HBCx-5, HBCx-24 and HBCx-4B untreated xenografts showed high levels of phosphorylated ERK, that were strongly decreased in Vandetanib-treated tumors (Fig. 3f) . The reduction was less pronounced in HBCx-14 tumor, which exhibited low ERK phosphorylation at baseline. By contrast, phosphorylation of S6 was not decreased in Vandetanib-treated xenografts (Supporting Information Fig. S6 ). We also measured the expression of P-4EBP1, another PI3 Kinase pathway downstream marker, which was unchanged in Vandetanibtreated tumors (data not shown).
These results indicate that Vandetanib impairs activation (phosphorylation) of receptors tyrosine kinase through inhibition of MAP Kinase pathway.
To further evaluate the effect of Vandetanib on the transcriptional activity of MAP Kinase and PI3 Kinase pathways, the expression of a selection of genes induced by these two pathways was evaluated by RT-PCR in order to identify dynamic changes associated with Vandetanib treatment. Transcription of genes induced by MAP Kinase pathway 23 (EGR1, ELK1, ELK3) was decreased in Vandetanib treated group in HBCx-5 and HBCx-24, and EGR1 was decreased in HBCx-4B and HBCx-14 (Supporting Information Fig. S7a ).
The expression levels of genes induced by PI3 Kinase pathway (HIF1A, HIF2A/EPAS1, GLUT1/SLC2A1, HMOX1, CA9) remained stable with treatment (Supporting Information Fig.  S7b) .
As Vandetanib has an anti-angiogenic effects, 24 we measured the expression of the three murine vascular endothelial growth factor receptors (Vegfr1, Vegfr2 and Vegfr3) and the murine Cd31 (Pecam1, platelet/endothelial cell adhesion molecule 1), used as a marker of endothelial cells, by RT-PCR analysis in treated and untreated tumors. Results showed a significant reduction of murine Cd31 gene expression, suggesting inhibition of tumor vasculature by treatment with Vandetanib. This reduction was associated with a decreased expression of Vegfr1, Vegfr2 and Vegfr3 murine genes (Fig.  4a) . IHC analysis of endothelial Cd31 expression confirmed a decreased Cd31-positive area in Vandetanib-treated tumors (Figs. 4b and 4c ).
In addition, we measured the expression of Ki67 by RT-PCR analysis and cleaved PARP by Western Blot and we did not find any significant changes between untreated and Vandetanib-treated tumors in the 4 PDX models (data not shown).
Finally, the relative area of necrotic tissue was determined visually in stained tissue sections, using interactive textual region detection morphometric image analysis of tumor sections. We found a significant increase of necrosis in HBCx-4B, HBCx-5 and a trend close to significance in the HBCx-24 PDX (Fig. 4d) . In this latter model, the percentage of necrosis present in untreated tumors was elevated (40-50%) (Fig. 4e) .
Overall, these results suggest that Vandetanib has antitumor activity mainly via MAPK pathway inhibition, inhibition of tumor vascularization and induction of necrosis.
Discussion
In this study, we evaluated the expression level of RET in a large cohort of patients breast tumors and PDX models of breast cancer and investigated the antitumor activity of Vandetanib in PDX models of HER21 and triple-negative breast cancer. Analysis of RET expression in patients tumors biopsies showed RET overexpression in 32.7% of all breast tumors. This high expression was mainly correlated with ER expression in agreement with other studies describing RET overexpression mainly in ERa-positive breast tumors. 6, 25 RET expression in a large cohort of 57 PDX models, including all subtypes of breast cancers, mirrored results obtained in patients tumors, with 26% of PDX models showing a high expression of RET. The overexpression was found mainly in the ER positive Group (83%) as compared to the two subgroups of ER negative tumors (11%).
If RET has been investigated preclinically as potential target in ER1 breast cancers, alone and combined to endocrine therapies, 7, 8 there are no preclinical data showing that RET could be a relevant target in the subset of ER negative tumors with RET overexpression. Since there is no specific inhibitor against RET, we evaluated the activity of Vandetanib, a multi tyrosine kinase targets with potent activity against RET, EGFR and VEGFR-2, approved for the treatment of locally advanced, or metastatic medullary thyroid cancer. 5, 26 Vandetanib had an impressive antitumor activity, with 43-57% of mice showing tumor regression, in both HER21 and triple negative models with high expression of RET or EGFR. The effect was associated with marked decrease in RET or EGFR phosphorylation and inhibition of the MAPK pathway. Inhibition of RET kinase activity in Vandetanib-treated tumors is also suggested by inhibition of FAK phosphorylation, as RET has been shown to directly bind to and activate FAK. 27, 28 Our findings are in agreement with previous studies showing inhibition of phospho-RET and phospho-ERK in Vandetanib-treated breast cancer cells 7, 8 and suggest that RET/EGFR inhibition mediates the tumor-specific effect of Vandetanib in these two models. Result obtained in the HBCx-5 (HER21) and HBCx-4B (triple-negative, EGFR1) PDX models, both established from lymph node metastases, are particularly interesting as they suggest that Vandetanib could represent an alternative treatment for locally advanced breast cancers, in a context of Trastuzumab and chemotherapy resistance. The HBCx-5 xenograft model was established from a patient who was resistant to Trastuzumab. 12 In the PDX model HBCx-14, with no expression of Vandetanib's main targets RET and EGFR, Vandetanib treatment decreased tumor growth but did not result in tumor regressions nor tumor stabilization. As Vandetanib has also activity against other tyrosine kinase receptors, 21, 22 its effect in this PDX could depend on the presence of other Vandetanib's targets and/or inhibition of angiogenesis. Indeed, this tumour showed high expression of the oncogene KIT, also known to be overexpressed in breast cancer and specially in TNBC, 29 and treatment by Vandetanib decreased KIT phosphorylation. As Vandetanib has also activity against KIT, 21, 22, 30 although lower than against EGFR and RET, the effect of Vandetanib in this PDX could rely on the presence of this RTK.
In addition to the activity on tumour cells, our results suggest that Vandetanib had an antiangiogenic effect in the four PDX models tested, as shown by the gene expression decrease of murine Vegf receptors and the endothelial marker Cd31. These results are consistent with other works that demonstrated the effect of Vandetanib on tumor angiogenesis in vivo. 18, 31 In the four PDX models of our study, Vandetanib treatment resulted in induction of necrosis, in agreement with other preclinical studies showing that tumors treated by Vandetanib had an increased proportion of necrosis without significant increase in cell apoptosis. 18, 32 Nevertheless, although we did not detect significant increased levels of cleaved PARP in treated tumors harvested at the end of treatment, we cannot completely exclude a possible induction of an apoptotic process at an early stage after treatment.
In conclusion, this work reveals for the first time the potential of Vandetanib in the treatment of ER negative breast tumors, resistant to other treatments such as Trastuzumab or chemotherapy. In PDX models with high expression of RET or EGFR, treatment by Vandetanib showed a strong tumor growth inhibition with tumor regression observed in about 50% of animals. This effect was associated with inhibition of RET or EGFR phosphorylation, MAPK signaling pathway and decreased expression of endothelial cell markers. As RET is expressed in < 10% of triple-negative and 20-40% of HER21 breast cancers (our results and published data), and EGFR in approximately 6% of breast cancer, 33 these populations could be eligible to receive Vandetanib as targeted therapy.
Although further studies and additional PDX are warranted to identify biomarkers of response to Vandetanib, that might be complicated by its poor selectivity, our data suggest that RET and EGFR expressing tumors could respond to treatment with tumor regression. In a clinical perspective, it would be useful to stratify breast cancer patients according to the expression of these targets in order to identify patients who could most likely benefit from Vandetanib treatment.
